NeuroMetrix (NeuroMetrix) Long-Term Capital Lease Obligation : $0.06 Mil (As of Mar. 2024)

View and export this data going back to 2004. Start your Free Trial

What is NeuroMetrix Long-Term Capital Lease Obligation?

NeuroMetrix's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.06 Mil.

NeuroMetrix's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($0.12 Mil) to Dec. 2023 ($0.09 Mil) and declined from Dec. 2023 ($0.09 Mil) to Mar. 2024 ($0.06 Mil).

NeuroMetrix's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($0.31 Mil) to Dec. 2022 ($0.21 Mil) and declined from Dec. 2022 ($0.21 Mil) to Dec. 2023 ($0.09 Mil).

NeuroMetrix Long-Term Capital Lease Obligation Historical Data

The historical data trend for NeuroMetrix's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroMetrix Long-Term Capital Lease Obligation Chart

NeuroMetrix Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.92

0.46

0.31

0.21

0.09

NeuroMetrix Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															0.18	0.15	0.12	0.09	0.06

NeuroMetrix (NAS:NURO) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

NeuroMetrix Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of NeuroMetrix's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroMetrix (NeuroMetrix) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NeuroMetrix Inc (NAS:NURO) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

4B Gill Street, Woburn, MA, USA, 01801

Website

https://www.neurometrix.com

NeuroMetrix Inc is a commercial-stage healthcare company. Its core business activities are integrated with in-house capabilities spanning product development, manufacturing, regulatory affairs and compliance, sales and marketing, and customer support. The company produces bioelectrical and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The product line of the company includes Wearable neuro-stimulation therapeutic devices and Point-of-care neuropathy diagnostic tests. The company operates in a single segment being Medical equipment and consumables.

Executives

Bradley M Fluegel	director	120 MONUMENT CIRCLE, INDIANAPOLIS IN 46204
Thomas T Higgins	officer: Chief Financial Officer
Topline Capital Management, Llc	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Topline Capital Partners, Lp	10 percent owner	544 EUCLID STREET, SANTA MONICA CA 90402
Mcbirney Collin	other: See Explanation in Footnotes	544 EUCLID STREET, SANTA MONICA CA 90402
Shai Gozani	director, officer: Chairman, President and CEO	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Francis X Mcgillin	officer: Senior VP, Consumer	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Avermaete David Van	director	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Krishnamurthy Balachandran	officer: S. VP and GM, International	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Nancy E Katz	director	CALYPTE BIOMEDICAL CORP, 1265 HARBOR BAY PKWY, ALAHEDA CA 94502
Neurometrix Inc	officer: Senior Vice President & GM
Walter Christensen	officer: Sr. VP, Global Sales	C/O NEUROMETRIX, INC., 62 FOURTH AVENUE, WALTHAM MA 02451
Timothy R Surgenor	director	100 FOXBOROUGH BOULEVARD, SUITE 240, FOXBOROUGH MA 02035
Deerfield Management Company, L.p. (series C)	10 percent owner	345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p.	10 percent owner	780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017